
    
      Overall, subjects with resectable, borderline-resectable and/or locally-advanced pancreatic
      cancer are eligible to be entered into the study. Each enrolled study subject will receive a
      single neoadjuvant pancreatic retrograde venous infusion (PRVI) administration of the
      gemcitabine/LipiodolÂ® emulsion.

      Complete enrollment in 12 months from date of enrollment of first study subject.
    
  